Abstract
Insulin glargine is a human insulin analog prepared by recombinant DNA technology and it is the first clinically useful extended-acting insulin analog preparation with a smooth 24-h time action profile. Recent data have included evidence of improved glycaemic control ( decrease glycaemia and Hba1c) and better satisfaction of patients with glargine treatment compared with NPH insulin.
The time of day at which insulin glargine is injected has no clinical influence on the level of glycae-mia during the day. Glargine is effective and safe long-acting insulin analog as a component of basal bolus therapy with type 1and type 2 diabetics and offers an advantage not only in blood glucose control but also glargine can decreased hypoglycaemia(particulary nocturnal).